New cocktail aims to boost remission in rare blood cancer
NCT ID NCT04624906
First seen Feb 04, 2026 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This phase II trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) improves outcomes for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 63 participants will receive the three-drug combo for up to a year. The main goal is to see how many achieve a very good partial response or complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Quebec - University Laval
Laval, Quebec, Canada
-
Cross Cancer Institute
Edmonton, Alberta, Canada
-
Hamilton Health Sciences Centre - Juravinksi
Hamilton, Ontario, Canada
-
McGill University Health Centre
Montreal, Quebec, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
The Ottawa Hospital
Ottawa, Ontario, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, Canada
-
Vancouver General Hospital
Vancouver, British Columbia, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Acalabrutinib (a targeted cancer drug) combined with bendamustine and rituximab (standard chemotherapy and immunotherapy)
What this could lead to
If successful, this combination could offer a more effective first-line treatment for Waldenstrom's macroglobulinemia, potentially leading to deeper and longer-lasting responses.
What could go wrong
This is a phase II trial with only 63 participants and no comparison group, so results are preliminary. The added drug (acalabrutinib) may increase side effects without improving outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.